GSK preps for Pfizer consumer health JV with £1B in product sell-offs: report

sale
GlaxoSmithKline has reportedly started selling off some non-core consumer products as it looks to raise £1 billion to cover the costs of a Pfizer OTC merger. (Getty Images Stock Photo)

GlaxoSmithKline and Pfizer are expecting to combine their consumer health businesses later this year with the aim of an eventual spinoff. But before that can happen, some products will have to go.

GSK has started selling off some non-core consumer products, Reuters reported, citing three sources familiar with the matter. Back in December when the merger deal was announced, the British drugmaker said it would cut around £1 billion ($1.26 billion) worth of assets within the unit to cover the costs of the integration.

RELATED: GSK, Pfizer go for radical makeovers with giant consumer combo destined for spinoff

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Separately, an update posted by the European Commission said GSK on Wednesday made commitments to win EU antitrust clearance. The regulator said it would decide by July 10 whether to accept the proposal.

GSK declined to comment on both matters.

Three portfolio bundles are up for grabs. GSK has already sent materials on Latin American drugs and Physiogel skin care brands to possible bidders, while bidding for some European drugs will kick off after the summer, the sources told Reuters.

One source said the Latin American franchise, which boasts revenues of about £90 million, could be sold to local players. Meanwhile, Takeda Pharmaceutical is also looking to sell its Latin American business to help pay off debt related to the Shire buyout, and Brazil’s largest drugmaker EMS Pharma could be the front-runner, Reuters previously reported.

The European products represent about 40% of the total £200 million to £300 million in revenues of the combined for-sale assets, according to one person, and it may be the most attractive. Some private equity firms and frequent pharmaceuticals buyers are said to be eyeing the package. Those include Advent International, CVC Capital Partners, Bain Capital and Cinven. Look familiar? These funds are reportedly also sizing up Bayer’s animal health unit.

In 2018, Advent bought Sanofi’s European generics business Zentiva for €1.9 billion ($2.2 billion). Around the same time, CVC shelled out €3.03 billion for Italian drugmaker Recordati. As for Bain and Cinven, they recently bought Germany’s Stada and took it private.

Earlier this month, Stada unveiled a deal to buy five skincare products and one pediatric cough remedy from GSK. “This will strengthen Stada’s position as a go-to partner in the European healthcare market, and will seize the opportunity to be a leading company in consumer health as well as generics," Stada CEO Peter Goldschmidt said in a statement at the time.

For GSK, folding in Pfizer’s OTC business will create a consumer giant with about $12.7 billion in sales, putting it ahead of rivals Johnson & Johnson, Bayer and Sanofi. To be run by GSK, the new unit will become the leader in areas such as pain relief, vitamin and mineral supplements, respiratory and oral care.

RELATED: Will pharma's exodus from consumer health continue into 2019? It sure looks that way

As Big Phama companies recently followed one another out of consumer health to focus on innovative medicines, GSK is also planning to spin off the joint venture into a separate corporation and list it in London within three years.

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.